What FDA Workforce Cuts Mean for the Biotech Industry

Last week, the Trump Administration, with Health Secretary Robert F. Kennedy Jr. at the helm, made sweeping workforce cuts to the Department of Health and Human Services (HHS). This move resulted in the lay off or reassignment of approximately 10,000 federal health workers, including scientists, doctors, senior leaders, and investigators across key agencies such as the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention, and the National Institutes of Health. Secretary Kennedy has since stated his intention to rehire 20 percent of the cut workforce, though whether that will happen remains to be seen. The cuts came on the heels of the departure of nearly 10,000 additional federal health workers who left the agencies when they accepted the administration’s Fork in the Road offer of voluntary resignation or early retirement.

Secretary Kennedy has announced a restructuring plan that aims to reduce the HHS workforce by nearly 25 percent—from 82,000 full-time employees to 62,000. Framed as an effort to streamline operations and enhance governmental efficiency, the plan’s destabilizing effects are already being felt, particularly within the FDA and the biotech sector.

FDA Cuts and Impact on the Biotech Industry

The recent FDA workforce cuts will have numerous problematic consequences throughout our public health system, one of which is uncertainty in the biotech industry. Though the exact number of affected FDA employees remains unknown, the restructuring plan aims to target 3,500 full-time FDA employees. Notably, the plan purports to avoid laying off or reassigning drug, medical device, or food reviewers, or inspectors; however, reports indicate that senior-level FDA scientists have been laid off. Even so, the loss of support personnel is expected to significantly disrupt the FDA’s operations, potentially leading to inefficiencies and uncertainties in the FDA regulatory process.

The biotech industry, which heavily relies on the FDA’s approval and regulation of new drugs and medical devices, is already grappling with the implications of these cuts. Experts caution that the loss of FDA support personnel will inevitably hamper the agency’s ability to efficiently process applications, which could have far-reaching consequences for biotech market dynamics and, ultimately, public health. Uncertainty and bureaucratic delays can have crushing consequences on any industry that, like biotech, is in the business of making intensive long-run investments in innovations that could benefit the public. 

To highlight the potential import of this development, consider that the FDA’s role in ensuring the safe commercialization of new drugs and medical devices is central to the success of biotech firms in the U.S. FDA approval timelines are not just a regulatory consideration in the biotech sector—they are fundamental to the valuation of biotech firms. Biotech firms often raise capital based on the projected timelines for each stage of the FDA approval process. As a firm advances from development to commercialization, its valuation can increase substantially. A delay in FDA approval could drastically alter the financial trajectory and longevity of a firm, underscoring the importance of a stable and efficient regulatory process. For the biotech industry, which thrives on startups and relatively immature firms that secure seed capital based on regulatory timelines, among other factors, the loss of smaller firms would significantly alter the sector’s landscape.

“Combine to Survive” and Biotech Market Implications

 Amidst the uncertainty in the biotech market caused by FDA workforce cuts, some biotech attorneys are counseling clients to consider adopting a “combine to survive” strategy. This approach encourages smaller biotech firms, particularly those in early developmental stages, to explore potential mergers with similarly sized companies or pursue exit strategies, such as mergers, acquisitions, or leasing, with larger medical device and pharmaceutical firms.  To the extent this happens, an unintended consequence of these cuts possibly could be less innovation as smaller firms, which in some cases drive important innovations, yield to survival strategies that will drive them into the arms of larger competitors. 

These concerns are readily apparent when one considers that smaller biotech firms are particularly vulnerable to regulatory delays. With limited cash reserves and resources, these firms may struggle to weather extended FDA approval timelines,  especially if they cannot afford to pay FDA user fees—fees paid to the agency to fund specific review timelines. Delays in the approval process may exacerbate the divide between user fee-funded and non-user-fee funded projects, further disadvantaging smaller firms that cannot afford to pay user fees.

That noted, these trends will also impact larger firms, which are positioned to invest in or acquire smaller firms, while also encountering new challenges. Uncertainty about the FDA’s ability to efficiently process applications may force larger firms to be more selective about their acquisitions. While smaller biotech firms may begin to consider exit strategies earlier in the development cycle, strategic buyers typically prefer to acquire firms in advanced stages of clinical trials, in which the risks associated with untested innovations are reduced.  All of this adds up to less innovation in the long run. 

Market Consolidation and Antitrust Considerations

Biotech industry experts had already forecasted an uptick in mergers and acquisitions within the sector in 2025. The ongoing uncertainty surrounding the FDA’s operational capacity and potential disruptions to its regulatory process may further accelerate this trend, driving further consolidation in the biotech market.

Antitrust practitioners should remain vigilant in monitoring these developments, considering potential impacts on competition within the biotech sector and ensuring that the industry remains innovative and competitive as it adjusts to these new realities.